Viridian Therapeutics, Inc. (VRDN) Financials

VRDN

Trailing 12 months to June 30, 2026

Revenue $71.1M +23220.3% YoY

Net Income -$387.0M -12.5% YoY

Free Cash Flow -$335.0M -8.2% YoY

Operating Cash Flow -$333.3M -7.9% YoY

Market Cap $2.2B as of Oct 5, 2026

Price / Sales 30.9x on $71.1M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 3.3x on $662.1M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VRDN SEC filings page.

Viridian Therapeutics, Inc. (VRDN) reported $71.1M in revenue over the twelve months to Jun 30, 2026, up 23220.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI VRDN FY2025 2026-10-04

Viridian remains a development-stage business: revenue is emerging, but R&D and external financing still determine its cash needs.

Operating cash flow of -$276M and free cash flow of -$277M were almost identical in FY2025, so cash consumption is not being driven by capital expenditure. That alignment means the reported accounting loss largely corresponds to operating investment rather than heavy spending on physical assets.

R&D was $338.9M against $70.8M of revenue, making research spending the dominant economic activity rather than a cost scaled to current sales. Revenue reached $70.8M in FY2025, yet the operating loss was $363.4M; the emerging revenue base has not absorbed development spending.

Financing cash flow of $426.7M exceeded operating cash outflow of $276.4M in FY2025, indicating that reported cash use was funded primarily externally rather than by operations. This funding posture sits alongside a 12.6x current ratio and reported liquidity of 38 months of the latest annual operating outflow, describing substantial short-term coverage without implying operating self-sufficiency.

Financial Health Signals

Financial Health Score 67/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Viridian Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Viridian Therapeutics, Inc. held $874.7M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $276.4M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Viridian Therapeutics, Inc. scores 62/100 among other emerging companies.

Dilution

Viridian Therapeutics, Inc. had 102M shares outstanding at the end of fiscal year 2025, against 81M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Viridian Therapeutics, Inc. scores 28/100 among other emerging companies.

R&D Intensity

Viridian Therapeutics, Inc. spent $338.9M on research and development in fiscal year 2025, which was 78.1% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Viridian Therapeutics, Inc. scores 96/100 among other emerging companies.

Revenue Progress

Viridian Therapeutics, Inc. reported revenue of $70.8M in fiscal year 2025, against $302K in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Viridian Therapeutics, Inc. scores 99/100 among other emerging companies.

Burn Trend

Viridian Therapeutics, Inc.'s operations used $276.4M of cash in fiscal year 2025, against $232.3M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Viridian Therapeutics, Inc. scores 29/100 among other emerging companies.

Balance Sheet

Viridian Therapeutics, Inc.'s cash, cash equivalents and investments came to $874.7M at the end of fiscal year 2025, against $177.3M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Viridian Therapeutics, Inc. scores 89/100 among other emerging companies.

Altman Z-Score Safe

5.20

Viridian Therapeutics, Inc. scores 5.20, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.2B) relative to total liabilities ($177.3M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/7

Viridian Therapeutics, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Viridian Therapeutics, Inc. reported a net loss of $342.6M while operations used $276.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Viridian Therapeutics, Inc. reported an operating loss of $363.4M against $4.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$284K

YoY+278.7%

QoQ+101.4%

5Y CAGR-23.6%

Viridian Therapeutics, Inc. generated $284K in revenue in Q2 2026. This represents an increase of 278.7% from the same quarter a year earlier. Against the prior quarter it is up 101.4%.

EBITDA

-$126.2M

YoY-18.3%

QoQ-8.7%

Viridian Therapeutics, Inc.'s EBITDA was -$126.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 18.3% from the same quarter a year earlier. Against the prior quarter it is down 8.7%.

Net Income

-$127.1M

YoY-26.2%

QoQ-21.2%

Viridian Therapeutics, Inc. reported -$127.1M in net income in Q2 2026. This represents a decrease of 26.2% from the same quarter a year earlier. Against the prior quarter it is down 21.2%.

EPS (Diluted)

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$106.6M

YoY-41.4%

QoQ+10.9%

Viridian Therapeutics, Inc. recorded an outflow of $106.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 41.4% from the same quarter a year earlier. Against the prior quarter it is up 10.9%.

Cash & Debt

$165.0M

YoY+40.6%

QoQ-6.4%

5Y CAGR+42.9%

Viridian Therapeutics, Inc. held $165.0M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

113M

YoY+38.7%

QoQ+9.9%

5Y CAGR+63.9%

10Y CAGR+26.5%

Viridian Therapeutics, Inc. had 113M shares outstanding in Q2 2026. This represents an increase of 38.7% from the same quarter a year earlier. Against the prior quarter it is up 9.9%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-19.2%

YoY+0.4pp

QoQ-2.7pp

5Y change-1.0pp

Viridian Therapeutics, Inc.'s ROE was -19.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 0.4 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.7 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$71.6M

YoY-17.4%

QoQ-7.8%

5Y CAGR+41.6%

Viridian Therapeutics, Inc. invested $71.6M in research and development in Q2 2026. This represents a decrease of 17.4% from the same quarter a year earlier. Against the prior quarter it is down 7.8%.

Capital Expenditures

$1.3M

YoY+3009.5%

QoQ+5578.3%

5Y CAGR+89.1%

10Y CAGR+28.0%

Viridian Therapeutics, Inc. invested $1.3M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 3009.5% from the same quarter a year earlier. Against the prior quarter it is up 5578.3%.

Share Buybacks

Not reported for Q2 2026.

VRDN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VRDN quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Revenue	$71.1M	$70.8M+23359.9%	$302K-3.8%	$314K-82.3%	$1.8M-40.2%	$3.0M+182.2%	$1.1M-76.5%	$4.5M-46.8%	$8.4M+109.5%	$4.0M+15.1%	$3.5M-39.1%	$5.7M-12.0%	$6.5M+18.1%	$5.5M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$2.5M+3.1%	$2.5M-26.6%	$3.4M+21.2%	$2.8M
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$929K-71.3%	$3.2M+3.7%	$3.1M+14.9%	$2.7M
R&D Expenses	$324.7M	$338.9M+42.3%	$238.3M+49.1%	$159.8M+58.3%	$100.9M+77.4%	$56.9M+101.0%	$28.3M-18.7%	$34.8M+14.4%	$30.4M+55.0%	$19.6M+43.3%	$13.7M+1266.5%	$1.0M+188.8%	$347K+54.2%	$225K
SG&A Expenses	$151.7M	$95.3M+56.0%	$61.1M-35.7%	$95.0M+170.0%	$35.2M+36.3%	$25.8M+94.5%	$13.3M+13.9%	$11.6M+5.4%	$11.0M+1.3%	$10.9M+61.1%	$6.8M-12.0%	$7.7M+12.2%	$6.9M+386.0%	$1.4M
Operating Income	-$405.2M	-$363.4M-21.5%	-$299.0M-17.5%	-$254.4M-89.5%	-$134.3M-68.5%	-$79.7M+27.8%	-$110.4M-162.9%	-$42.0M-26.9%	-$33.1M-24.7%	-$26.5M-56.2%	-$17.0M-51.8%	-$11.2M-62.9%	-$6.9M-3385.8%	-$197K
EBITDA	N/A	-$362.9M-21.6%	-$298.5M-17.6%	-$253.9M-89.4%	-$134.0M-68.4%	-$79.6M+27.7%	-$110.1M-164.2%	-$41.7M-27.1%	-$32.8M-25.1%	-$26.2M-57.5%	-$16.6M-51.3%	-$11.0M-63.7%	-$6.7M-13620.4%	-$49K
Interest Expense	$15.7M	$4.9M+125.2%	$2.2M+65.1%	$1.3M+166.2%	$500K+16566.7%	$3K-99.4%	$508K-39.2%	$835K-4.4%	$873K+127.9%	$383K+303.2%	$95K-32.6%	$141K-86.2%	$1.0M-47.9%	$2.0M
Income Tax	N/A	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	N/A
Net Income	-$387.0M	-$342.6M-26.9%	-$269.9M-13.5%	-$237.7M-83.0%	-$129.9M-63.6%	-$79.4M+28.3%	-$110.7M-164.4%	-$41.9M-28.0%	-$32.7M-23.4%	-$26.5M-53.5%	-$17.3M-52.5%	-$11.3M-43.6%	-$7.9M-265.3%	-$2.2M
EPS (Basic)	N/A	N/A	N/A	-$5.31-31.1%	-$4.05+39.2%	-$6.66+78.6%	-$31.13	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	N/A	N/A	-$5.31-31.1%	-$4.05	-$6.66	-$31.13	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	N/A	N/A	45M+39.5%	32M	12M	4M	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$284K+278.7%	$141K+95.8%	$132K+83.3%	$70.6M+81958.1%	$75K+4.2%	$72K0.0%	$72K0.0%	$86K+19.4%
R&D Expenses	$71.6M-17.4%	$77.6M+1.0%	$89.2M+24.0%	$86.3M+24.7%	$86.6M+54.2%	$76.8M+87.7%	$72.0M+86.6%	$69.2M+127.6%
SG&A Expenses	$55.0M+171.9%	$38.7M+126.2%	$33.7M+116.1%	$24.3M+68.8%	$20.2M+25.8%	$17.1M+13.8%	$15.6M-52.8%	$14.4M-31.1%
Operating Income	-$126.3M-18.3%	-$116.2M-23.8%	-$122.7M-40.3%	-$40.0M+52.1%	-$106.8M-47.9%	-$93.9M-67.9%	-$87.5M-22.4%	-$83.5M-63.0%
EBITDA	-$126.2M-18.3%	-$116.0M-23.8%	-$122.6M-40.4%	-$39.9M+52.1%	-$106.7M-48.0%	-$93.7M-68.2%	-$87.3M-22.5%	-$83.3M-63.1%
Interest Expense	$8.3M+1516.1%	$3.5M+529.5%	$3.3M+586.8%	$560K+5.9%	$514K-13.9%	$550K-6.3%	$484K+46.2%	$529K-11.8%
Net Income	-$127.1M-26.2%	-$104.9M-20.7%	-$120.4M-51.1%	-$34.6M+54.9%	-$100.7M-55.0%	-$86.9M-79.0%	-$79.7M-19.2%	-$76.7M-60.9%
EPS (Basic)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$1.15-5.5%
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$1.15
Diluted Shares (Avg)	N/A	N/A	N/A	N/A	82M+27.8%	81M+33.1%	N/A	66M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.

VRDN Balance Sheet

VRDN quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Total Assets	$899.4M+21.1%	$742.4M+51.4%	$490.4M+12.7%	$435.1M+113.6%	$203.7M+55.2%	$131.3M+333.7%	$30.3M-54.3%	$66.1M+26.0%	$52.5M+112.0%	$24.8M+91.9%	$12.9M+59.5%	$8.1M+120.2%	$3.7M
Current Assets	$894.2M+21.1%	$738.5M+51.8%	$486.5M+12.8%	$431.2M+115.4%	$200.2M+54.4%	$129.6M+335.8%	$29.7M-54.5%	$65.4M+26.0%	$51.9M+117.2%	$23.9M+103.5%	$11.7M+72.9%	$6.8M+230.2%	$2.1M
Cash & Equivalents	$212.4M+113.2%	$99.6M-3.1%	$102.8M-33.9%	$155.6M+267.8%	$42.3M-7.8%	$45.9M+84.7%	$24.8M-23.8%	$32.6M-31.3%	$47.4M+114.6%	$22.1M	N/A	$5.1M+2349.3%	$209K
Short-Term Investments	$662.3M+7.2%	$618.0M+65.0%	$374.5M+39.3%	$269.0M+73.9%	$154.7M+89.2%	$81.7M+3989.1%	$2.0M-93.3%	$29.9M	$0	$0	N/A	$0	$0
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$64K-65.8%	$187K+4.5%	$179K-49.9%	$357K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	$108K+350.0%	$24K-98.4%	$1.5M+7180.0%	$20K-94.9%	$394K-63.8%	$1.1M+9.5%	$994K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A	$0	$0
Total Liabilities	$177.3M+150.5%	$70.8M+46.2%	$48.4M+20.9%	$40.0M+150.3%	$16.0M+42.6%	$11.2M-22.7%	$14.5M-2.0%	$14.8M+6.0%	$14.0M-83.9%	$86.7M+49.0%	$58.2M+2673.7%	$2.1M-92.4%	$27.6M
Current Liabilities	$70.7M+47.7%	$47.9M+79.7%	$26.6M-20.1%	$33.3M+144.6%	$13.6M+27.7%	$10.7M+4.9%	$10.2M+51.2%	$6.7M+72.8%	$3.9M-43.4%	$6.9M+179.0%	$2.5M+24.1%	$2.0M-92.7%	$27.3M
Non-Current Liabilities	$106.6M+365.5%	$22.9M+5.2%	$21.8M+226.0%	$6.7M+183.3%	$2.4M+333.3%	$544K-87.4%	$4.3M-46.4%	$8.1M-19.9%	$10.1M-87.4%	$79.8M+43.2%	$55.7M+51022.9%	$109K-57.9%	$259K
Long-Term Debt	N/A	$20.6M+1.9%	$20.2M+335.0%	$4.6M	$0	N/A	$7.7M-23.3%	$10.0M0.0%	$10.0M	N/A	N/A	N/A	N/A
Total Equity	$722.2M+7.5%	$671.6M+51.9%	$442.0M+11.9%	$395.1M+110.5%	$187.7M+56.4%	$120.0M+661.9%	$15.8M-69.3%	$51.3M+33.3%	$38.5M+162.2%	-$61.9M-36.7%	-$45.3M-856.0%	$6.0M+125.1%	-$23.9M
Retained Earnings	-$1.3B-34.4%	-$995.9M-37.2%	-$725.9M-48.7%	-$488.2M-36.2%	-$358.3M-28.5%	-$278.9M-65.8%	-$168.2M-33.2%	-$126.3M-34.9%	-$93.6M-39.5%	-$67.1M-273.3%	-$18.0M-170.6%	-$6.6M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$1.1B+88.4%	$789.0M+19.4%	$899.4M+21.1%	$577.1M-25.2%	$582.3M-0.6%	$661.0M+4.9%	$742.4M+51.4%	$771.9M+134.8%
Current Assets	$1.1B+86.8%	$784.7M+19.4%	$894.2M+21.1%	$571.9M-25.5%	$578.8M-0.5%	$657.2M+4.9%	$738.5M+51.8%	$767.4M+137.0%
Cash & Equivalents	$165.0M+40.6%	$176.3M+51.7%	$212.4M+113.2%	$169.6M-15.3%	$117.3M+9.0%	$116.2M+26.8%	$99.6M-3.1%	$200.3M+79.5%
Short-Term Investments	$816.5M+83.1%	$585.8M+12.6%	$662.3M+7.2%	$321.3M-41.9%	$446.0M-3.8%	$520.4M-0.2%	$618.0M+65.0%	$552.9M+174.5%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$435.1M+548.0%	$153.0M+170.8%	$177.3M+150.5%	$74.2M+15.2%	$67.2M+19.2%	$56.5M+18.1%	$70.8M+46.2%	$64.4M+42.5%
Current Liabilities	$63.8M+21.3%	$51.8M+53.6%	$70.7M+47.7%	$50.7M+22.6%	$52.6M+43.0%	$33.7M+29.1%	$47.9M+79.7%	$41.4M+77.9%
Non-Current Liabilities	$371.3M+2448.7%	$101.2M+344.2%	$106.6M+365.5%	$23.5M+1.9%	$14.6M-25.5%	$22.8M+4.9%	$22.9M+5.2%	$23.0M+5.0%
Long-Term Debt	N/A	N/A	N/A	$20.9M+1.8%	$12.4M-29.4%	$20.7M+1.8%	$20.6M+1.9%	$20.5M+2.6%
Total Equity	$662.1M+28.5%	$636.0M+5.2%	$722.2M+7.5%	$503.0M-28.9%	$515.2M-2.7%	$604.5M+3.8%	$671.6M+51.9%	$707.5M+149.5%
Retained Earnings	-$1.6B-32.7%	-$1.4B-33.3%	-$1.3B-34.4%	-$1.2B-33.0%	-$1.2B-41.0%	-$1.1B-39.8%	-$995.9M-37.2%	-$916.1M-39.0%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

VRDN Cash Flow Statement

VRDN quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Cash Flow	-$333.3M	-$276.4M-19.0%	-$232.3M-26.1%	-$184.2M-96.3%	-$93.8M-71.9%	-$54.6M-83.3%	-$29.8M+17.4%	-$36.1M-34.3%	-$26.8M+4.7%	-$28.2M-90.9%	-$14.8M-113.9%	-$6.9M-211.7%	-$2.2M-89.5%	-$1.2M
Depreciation & Amortization	N/A	$460K-14.8%	$540K+3.4%	$522K+104.7%	$255K+112.5%	$120K-49.8%	$239K-17.0%	$288K+2.5%	$281K-8.8%	$308K-9.7%	$341K+85.3%	$184K+27.8%	$144K-2.7%	$148K
Stock-Based Compensation	N/A	$44.3M+5.1%	$42.1M-37.3%	$67.2M+239.9%	$19.8M+36.6%	$14.5M+296.8%	$3.6M-8.2%	$4.0M+7.9%	$3.7M+52.7%	$2.4M+1116.7%	$198K-93.4%	$3.0M-29.9%	$4.3M	N/A
Capital Expenditures	$1.7M	$495K-3.1%	$511K-43.1%	$898K+12.7%	$797K+135.8%	$338K+704.8%	$42K-50.0%	$84K-81.1%	$445K+80.9%	$246K-1.6%	$250K+103.3%	$123K-53.8%	$266K+5220.0%	$5K
Free Cash Flow	-$335.0M	-$276.9M-18.9%	-$232.8M-25.8%	-$185.1M-95.6%	-$94.6M-72.3%	-$54.9M-84.2%	-$29.8M+17.5%	-$36.1M-32.4%	-$27.3M+4.0%	-$28.4M-89.4%	-$15.0M-113.7%	-$7.0M-183.2%	-$2.5M-111.3%	-$1.2M
Investing Cash Flow	-$367.2M	-$37.6M+83.6%	-$228.7M-142.6%	-$94.3M+18.1%	-$115.1M-55.0%	-$74.3M-47.2%	-$50.5M-278.8%	$28.2M+194.4%	-$29.9M-2992.4%	$1.0M+513.6%	-$250K-163.2%	-$95K+65.3%	-$274K-4666.7%	$6K
Financing Cash Flow	$748.2M	$426.7M-6.8%	$457.7M+102.8%	$225.7M-30.0%	$322.2M+157.2%	$125.3M+23.7%	$101.3M+144630.0%	$70K-99.8%	$41.9M-20.1%	$52.5M+230.5%	$15.9M+24.9%	$12.7M+71.8%	$7.4M+487.5%	$1.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$285K
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$2K	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$105.3M-39.7%	-$119.7M-29.1%	-$23.8M+67.6%	-$84.6M-25.0%	-$75.4M-63.6%	-$92.7M-104.9%	-$73.3M-93.0%	-$67.7M-73.7%
Depreciation & Amortization	$117K+3.5%	$121K+3.4%	$120K-2.4%	$110K-15.4%	$113K-20.4%	$117K-19.3%	$123K-18.0%	$130K-3.7%
Stock-Based Compensation	$17.0M+56.6%	$13.4M+31.0%	N/A	$11.3M+29.0%	$10.8M-7.8%	$10.2M-19.5%	N/A	$8.7M-35.9%
Capital Expenditures	$1.3M+3009.5%	$23K-73.3%	$240K+110.5%	$127K-56.7%	$42K-59.6%	$86K	$114K+137.5%	$293K-27.5%
Free Cash Flow	-$106.6M-41.4%	-$119.7M-29.0%	-$24.0M+67.3%	-$84.7M-24.6%	-$75.4M-63.4%	-$92.7M-105.1%	-$73.4M-93.0%	-$68.0M-72.6%
Investing Cash Flow	-$231.2M-405.3%	$77.3M-22.8%	-$339.4M-439.5%	$126.1M+248.9%	$75.7M+22.2%	$100.1M+170.0%	-$62.9M+62.9%	-$84.7M-276.2%
Financing Cash Flow	$325.1M+42455.1%	$6.4M-31.0%	$405.9M+1042.6%	$10.9M-95.6%	$764K+607.4%	$9.2M-94.8%	$35.5M-82.1%	$245.0M+1485.2%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

VRDN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VRDN quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	26.7%-30.0pp	56.7%+8.6pp	48.1%-1.3pp	49.4%
Operating Margin	-512.9%	-99018.2%	-81035.0%	-7579.2%	-2690.8%	-10512.4%	-941.0%	-394.5%	-662.8%	-488.6%	-196.1%	-105.9%	-3.6%
Net Margin	-483.6%	-89370.9%	-75700.6%	-7330.7%	-2679.7%	-10544.3%	-938.6%	-390.0%	-662.3%	-496.8%	-198.5%	-121.7%	-39.3%
Return on Equity	-47.4%-7.3pp	-40.2%+13.6pp	-53.8%-20.9pp	-32.9%+9.4pp	-42.3%+49.9pp	-92.2%+173.6pp	-265.8%-202.1pp	-63.7%+5.1pp	-68.8%	N/A	N/A	-131.7%	N/A
Return on Assets	-38.1%-1.7pp	-36.4%+12.1pp	-48.5%-18.6pp	-29.9%+9.1pp	-39.0%+45.4pp	-84.4%+54.0pp	-138.4%-88.9pp	-49.4%+1.1pp	-50.5%+19.3pp	-69.8%+18.0pp	-87.8%+9.7pp	-97.5%-38.7pp	-58.8%
Current Ratio	12.65-2.8x	15.43-2.8x	18.26+5.3x	12.93-1.7x	14.68+2.5x	12.14+9.2x	2.92-6.8x	9.71-3.6x	13.31+9.8x	3.47-1.3x	4.75+1.3x	3.41+3.3x	0.08
Debt-to-Equity	0.25+0.2x	0.030.0x	0.050.0x	0.010.0x	0.00-0.1x	0.09-0.4x	0.49+0.3x	0.19-0.1x	0.26	N/A	N/A	0.35	N/A
Asset Turnover	0.08+0.1x	0.000.0x	0.000.0x	0.000.0x	0.010.0x	0.01-0.1x	0.150.0x	0.13+0.1x	0.08-0.1x	0.14-0.3x	0.44-0.4x	0.80-0.7x	1.50
FCF Margin	-390.8%	-77096.0%	-58938.9%	-5340.6%	-1853.5%	-2840.1%	-810.1%	-325.4%	-709.8%	-431.6%	-123.0%	-38.2%-16.9pp	-21.4%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Margin	-44460.6%	-82389.4%	-92991.7%	-56.7%	-142356.0%	-130369.4%	-121487.5%	-97069.8%
Net Margin	-44760.2%	-74397.9%	-91177.3%	-49.0%	-134313.3%	-120711.1%	-110661.1%	-89173.3%
Return on Equity	-19.2%+0.4pp	-16.5%-2.1pp	-16.7%-4.8pp	-6.9%+4.0pp	-19.6%-7.3pp	-14.4%-6.1pp	-11.9%+3.3pp	-10.8%+6.0pp
Return on Assets	-11.6%+5.7pp	-13.3%-0.2pp	-13.4%-2.6pp	-6.0%+4.0pp	-17.3%-6.2pp	-13.2%-5.5pp	-10.7%+2.9pp	-9.9%+4.6pp
Current Ratio	16.95+5.9x	15.15-4.3x	12.65-2.8x	11.28-7.3x	11.01-4.8x	19.49-4.5x	15.43-2.8x	18.55+4.6x
Debt-to-Equity	0.66+0.6x	0.24+0.2x	0.25+0.2x	0.040.0x	0.020.0x	0.030.0x	0.030.0x	0.030.0x
Asset Turnover	0.000.0x	0.000.0x	0.000.0x	0.12+0.1x	0.000.0x	0.000.0x	0.000.0x	0.000.0x
FCF Margin	-37545.8%	-84877.3%	-18177.3%	-120.1%	-100553.3%	-128804.2%	-102008.3%	-79068.6%

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Viridian Therapeutics, Inc. VRDN	FY2025	$70.8M	-$342.6M	N/A	$2.2B	67/100
Vera Therapeutics, Inc. VERA	FY2025	N/A	-$299.6M	N/A	$2.2B	—
Aurinia Pharmaceuticals Inc AUPH	FY2025	$283.1M	$287.2M	N/A	$2.1B	56/100
Cidara Therapeutics, Inc. CDTX	FY2024	$1.3M	-$169.8M	N/A	$7.0B	49/100
Edgewise Therapeutics, Inc. EWTX	FY2025	N/A	-$168K	N/A	$4.5B	—
Sarepta Therapeutics,, Inc. SRPT	FY2025	$2.2B	-$713.4M	-32.5%	$1.8B	44/100

Where Viridian Therapeutics, Inc. Ranks

Frequently Asked Questions

What is Viridian Therapeutics, Inc.'s annual revenue?

Viridian Therapeutics, Inc. (VRDN) reported $70.8M in total revenue for fiscal year 2025. This represents a 23359.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Viridian Therapeutics, Inc.'s revenue growing?

Viridian Therapeutics, Inc. (VRDN) revenue grew by 23359.9% year-over-year, from $302K to $70.8M in fiscal year 2025.

Is Viridian Therapeutics, Inc. profitable?

No, Viridian Therapeutics, Inc. (VRDN) reported a net income of -$342.6M in fiscal year 2025.

What is Viridian Therapeutics, Inc.'s EBITDA?

Viridian Therapeutics, Inc. (VRDN) had EBITDA of -$362.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Viridian Therapeutics, Inc.'s return on equity (ROE)?

Viridian Therapeutics, Inc. (VRDN) has a return on equity of -47.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Viridian Therapeutics, Inc.'s free cash flow?

Viridian Therapeutics, Inc. (VRDN) recorded an outflow of $276.9M in free cash flow during fiscal year 2025. This represents a -18.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Viridian Therapeutics, Inc.'s operating cash flow?

Viridian Therapeutics, Inc. (VRDN) recorded an outflow of $276.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Viridian Therapeutics, Inc.'s total assets?

Viridian Therapeutics, Inc. (VRDN) had $899.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Viridian Therapeutics, Inc.'s capital expenditures?

Viridian Therapeutics, Inc. (VRDN) invested $495K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Viridian Therapeutics, Inc. spend on research and development?

Viridian Therapeutics, Inc. (VRDN) invested $338.9M in research and development during fiscal year 2025.

How many shares does Viridian Therapeutics, Inc. have outstanding?

Viridian Therapeutics, Inc. (VRDN) had 102M shares outstanding as of fiscal year 2025.

What is Viridian Therapeutics, Inc.'s current ratio?

Viridian Therapeutics, Inc. (VRDN) had a current ratio of 12.65 as of fiscal year 2025, which is generally considered healthy.

What is Viridian Therapeutics, Inc.'s debt-to-equity ratio?

Viridian Therapeutics, Inc. (VRDN) had a debt-to-equity ratio of 0.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Viridian Therapeutics, Inc.'s return on assets (ROA)?

Viridian Therapeutics, Inc. (VRDN) had a return on assets of -38.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Viridian Therapeutics, Inc.'s P/E ratio?

Viridian Therapeutics, Inc. (VRDN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $2.2B as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Viridian Therapeutics, Inc.'s price-to-sales ratio?

Viridian Therapeutics, Inc. (VRDN) trades at 30.9x sales, its market capitalization divided by revenue of $71.1M revenue, trailing 12 months to June 30, 2026. The market capitalization is $2.2B as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Viridian Therapeutics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Viridian Therapeutics, Inc. (VRDN) held $874.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $276.4M over that year. Dividing the one by the other, the reported balance equals about 38 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Viridian Therapeutics, Inc.'s Altman Z-Score?

Viridian Therapeutics, Inc. (VRDN) has an Altman Z-Score of 5.20, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Viridian Therapeutics, Inc.'s Piotroski F-Score?

Viridian Therapeutics, Inc. (VRDN) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Viridian Therapeutics, Inc.'s earnings high quality?

Viridian Therapeutics, Inc. (VRDN) reported a net loss of $342.6M while operations used $276.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Viridian Therapeutics, Inc. cover its interest payments?

Viridian Therapeutics, Inc. (VRDN) reported an operating loss of $363.4M against $4.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Viridian Therapeutics, Inc.?

Viridian Therapeutics, Inc. (VRDN) scores 67 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.